Bone Marrow Transplant Cures Child with Leukemia of Peanut Allergy

While it was previously known that a bone marrow transplant (BMT) can confer the donor's peanut allergy onto the recipient, a case has been found in which the recipient was cured of peanut allergy following a BMT.

According to research presented at the American College of Allergy, Asthma and Immunology annual meeting, a 10-year-old patient with acute lymphocytic leukemia (ALL) was found to be cured of his peanut allergy after undergoing an allogenic bone marrow transplant.

Transplant leads to allergy cure

Lead study author Yong Luo, M.D., Ph.D. said that the child had been diagnosed with a peanut allergy at age 15 months, following a severe reaction to peanuts involving hives and vomiting.

At age 10, he was treated for ALL by a bone marrow transplant from a donor without any known allergies, and he appeared to be cured of the allergy.

The cure was confirmed by allergists, who conducted what's known as an oral food challenge, a test carried out under strong medical scrutiny because it involves peanut ingestion. The child in question showed no signs of allergy from the test.

While researchers could offer no immediate explanation for the cure, it was noted by study co-author Steven Weiss, M.D., Ph.D., that the case boosts the evidence indicating that "genetic modification during the early stages of immune cell development in bone marrow may play a large role in causing allergy."

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap